Effets du traitement à l'hémine sur l'expansion et la différenciation des cellules souches hématopoïétiques
|Advisor:||Doyon, Yannick; Laganière, Josée|
|Abstract:||Human hemin, commercialized as Normosang® or Panhematin®, is a therapeutic agent approved for the treatment of acute attacks of porphyria, a genetic disease causing a malfunction of the heme biosynthesis pathway. Recently, the treatment of a patient with severe autoimmune hemolytic anemia and reticulocytopenia was managed by a hematologist from Héma-Québec. The treatment of this patient with Normosang® has, among other things, contributed to the increasing erythrocyte levels and contributed to the complete recovery of this patient. The aim of this project was to evaluate the effects of hemin on the expansion and differentiation of hematopoietic cord blood stem cells in a culture media favoring erythroid differentiation. Results show that hemin has a positive effect on cell growth during their erythroid differentiation. The results show that hemin also appears to have an effect on erythroid precursors. Differentiation analysis points to a possible role for hemin in the stimulation of erythroid differentiation as well as enucleation. More knowledge on the subject could ultimately support a larger spectrum of clinical applications.|
|Document Type:||Mémoire de maîtrise|
|Open Access Date:||5 July 2018|
|Collection:||Thèses et mémoires|
All documents in CorpusUL are protected by Copyright Act of Canada.